46 related articles for article (PubMed ID: 28038857)
1. Outcomes of the transformation of follicular lymphoma to diffuse large B-cell lymphoma in the rituximab era: A population-based study.
Zheng W; Liu M; Guan L; Wang S
Cancer Med; 2024 Apr; 13(8):e7120. PubMed ID: 38629251
[TBL] [Abstract][Full Text] [Related]
2. Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy.
Farooq U; Maurer MJ; Thompson CA; Thanarajasingam G; Inwards DJ; Micallef I; Macon W; Syrbu S; Lin T; Lin Y; Ansell SM; Nowakowski GS; Habermann TM; Cerhan JR; Link BK
Br J Haematol; 2017 Oct; 179(1):50-60. PubMed ID: 28653407
[TBL] [Abstract][Full Text] [Related]
3. Urelumab alone or in combination with rituximab in patients with relapsed or refractory B-cell lymphoma.
Timmerman J; Herbaux C; Ribrag V; Zelenetz AD; Houot R; Neelapu SS; Logan T; Lossos IS; Urba W; Salles G; Ramchandren R; Jacobson C; Godwin J; Carpio C; Lathers D; Liu Y; Neely J; Suryawanshi S; Koguchi Y; Levy R
Am J Hematol; 2020 May; 95(5):510-520. PubMed ID: 32052473
[TBL] [Abstract][Full Text] [Related]
4. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL).
Ghielmini M; Vitolo U; Kimby E; Montoto S; Walewski J; Pfreundschuh M; Federico M; Hoskin P; McNamara C; Caligaris-Cappio F; Stilgenbauer S; Marcus R; Trneny M; Dreger P; Montserrat E; Dreyling M;
Ann Oncol; 2013 Mar; 24(3):561-76. PubMed ID: 23175624
[TBL] [Abstract][Full Text] [Related]
5. Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.
Tao L; Clarke CA; Rosenberg AS; Advani RH; Jonas BA; Flowers CR; Keegan THM
Br J Haematol; 2017 Jul; 178(1):72-80. PubMed ID: 28542862
[TBL] [Abstract][Full Text] [Related]
6. The impact of marginalization on diffuse large B-cell lymphoma overall survival: a retrospective cohort study.
Arya S; Mozessohn L; Gong I; Faught N; Liu N; Singh S; Chan K; Cheung MC
Leuk Lymphoma; 2024 May; 65(5):629-637. PubMed ID: 38265355
[TBL] [Abstract][Full Text] [Related]
7. [Pathobiology and its clinical relevance in diffuse large B-cell lymphoma].
Ennishi D
Rinsho Ketsueki; 2023; 64(9):1026-1031. PubMed ID: 37899179
[TBL] [Abstract][Full Text] [Related]
8. Prognostic modeling in diffuse large B-cell lymphoma in the era of immunochemotherapy: Where do we go from here?
Koff JL; Flowers CR
Cancer; 2017 Sep; 123(17):3222-3225. PubMed ID: 28464215
[No Abstract] [Full Text] [Related]
9. Survival of patients with transformed follicular lymphoma in the United States: a multiple cohort study.
Vaughn JL; Epperla N
Biomark Res; 2023 Sep; 11(1):84. PubMed ID: 37759262
[TBL] [Abstract][Full Text] [Related]
10. Outcome of Patients with Diffuse Large B-Cell Lymphoma Relapsing after Autologous Transplant before Availability of CAR-T Cell Treatment.
von Matt S; Bacher U; Banz Y; Taleghani BM; Novak U; Pabst T
Mediterr J Hematol Infect Dis; 2023; 15(1):e2023025. PubMed ID: 37180203
[TBL] [Abstract][Full Text] [Related]
11. Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma.
Fu K; Weisenburger DD; Choi WW; Perry KD; Smith LM; Shi X; Hans CP; Greiner TC; Bierman PJ; Bociek RG; Armitage JO; Chan WC; Vose JM
J Clin Oncol; 2008 Oct; 26(28):4587-94. PubMed ID: 18662967
[TBL] [Abstract][Full Text] [Related]
12. Survival of patients with transformed lymphoma in the rituximab era.
Guirguis HR; Cheung MC; Piliotis E; Spaner D; Berinstein NL; Imrie K; Zhang L; Buckstein R
Ann Hematol; 2014 Jun; 93(6):1007-14. PubMed ID: 24414374
[TBL] [Abstract][Full Text] [Related]
13. De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.
Alinari L; Gru A; Quinion C; Huang Y; Lozanski A; Lozanski G; Poston J; Venkataraman G; Oak E; Kreisel F; Park SI; Matthews S; Abramson JS; Iris Lim H; Martin P; Cohen JB; Evens A; Al-Mansour Z; Singavi A; Fenske TS; Blum KA
Am J Hematol; 2016 Jun; 91(4):395-9. PubMed ID: 26800311
[TBL] [Abstract][Full Text] [Related]
14. DLBCL arising from indolent lymphomas: How are they different?
Parry EM; Roulland S; Okosun J
Semin Hematol; 2023 Nov; 60(5):277-284. PubMed ID: 38072721
[TBL] [Abstract][Full Text] [Related]
15. Transformation in follicular lymphoma: biology, prognosis, and therapeutic options.
Wong E; Dickinson M
Curr Oncol Rep; 2012 Oct; 14(5):424-32. PubMed ID: 22865028
[TBL] [Abstract][Full Text] [Related]
16. Similar prognosis of transformed and de novo diffuse large B-cell lymphomas in patients treated with immunochemotherapy.
Sorigue M; Garcia O; Baptista MJ; Sancho JM; Tapia G; Mate JL; Feliu E; Navarro JT; Ribera JM
Med Clin (Barc); 2017 Mar; 148(6):243-249. PubMed ID: 28038857
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
